Latest News

The launch coincides with the company’s 30th year of operations and reinforces its strategy of building an integrated healthcare system across Uganda.

Jascayd acts as the first phosphodiesterase 4B (PDE4B) inhibitor approved for these indications, offering both antifibrotic and immunomodulatory activity.

The development marks another milestone for the West African nation, which was certified free of wild poliovirus in 2019 by the Africa Regional Commission for the Certification of Poliomyelitis Eradication.

The treatment is approved in the United States for adults and pediatric patients aged six months and older, making it one of the few targeted therapies available for this condition.

Health authorities in DRC and Uganda have already activated emergency response mechanisms, including contact tracing, case isolation, infection prevention measures, and enhanced treatment services.

Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.

The company will present its newly CE-marked AI contouring solution at the annual congress of the European Society for Radiotherapy and Oncology in Stockholm.

The continental framework outlines actions to expand newborn screening, early diagnosis, treatment, surveillance, financing, advocacy, local production of commodities, research, and integrated care systems.

Globally, new HIV infections declined by 40% between 2010 and 2024, while the number of people requiring interventions for neglected tropical diseases dropped by 36% during the same period.

MIEBO contains the active ingredient perfluorohexyloctane and is the first prescription eye drop designed to target tear evaporation directly, one of the primary causes of dry eye disease.